Patients who underwent core needle biopsy are more likely to have poor-risk disease features and inadequate tissue for molecular analyses. loom.ly/GAj5SJU #clinicaltrialsandobservations #lymphoidneoplasia

Great news for patients in need - non-covalent BTKi pirtobrutinib @LoxoLillyOnc approved for mantle cell lymphoma. Michael Wang, MD Toby Eyre Chan Cheah John Pagel MD PhD

MIRACLE, an investigator-initiated study of MRD-guided, time-limited frontline therapy with pirtobrutinib and venetoclax for CLL/SLL, sponsored by Loxo@Lilly Oncology Medical, is now open Mayo Clinic Comprehensive Cancer Center. clinicaltrials.gov/ct2/show/NCT05…

Brexu-cel for R/R MCL in standard-of-care practice. Comparable results to ZUMA-2, although follow-up still short. Great collaboration among US Lymphoma CART Consortium. Mayo Clinic Comprehensive Cancer Center MD Anderson Cancer Center Moffitt Cancer Center ascopubs.org/doi/pdf/10.120…

Celebrating the milestone birthdays of two international treasures in lymphoma! Happy birthday Toms (Witzig and Habermann)! And yes, those are “rituximab” cupcakes Mayo Clinic Comprehensive Cancer Center #MayoLymphoma Greg Carrie Thompson, MD Paul Hampel Yucai Wang, MD, PhD Yi Lin Jonas Paludo

Pirtobrutinib in covalent BTKi pre-treated relapsed and refractory #MCL ➡️ fal.cn/3yiHN Journal of Clinical Oncology Michael Wang, MD Nirav Shah Toby Eyre Chan Cheah Kami Maddocks Krish Patel Tim Fenske

CD3xCD20 bispecific antibody for R/R LBCL. Here we go. Epicoritamab. More to come. prnewswire.com/news-releases/…

Learn about the latest developments in cancer treatment at our upcoming CME course. Updates in Cancer Novel Immunotherapies is October 5-7 in Rochester, Minnesota, and via livestream. Registration and full progarm schedule: mayocl.in/42XFPq5

Super productive LEO Cohort Study retreat in NYC. Important #lymphoma studies across working groups and an unique opportunity to exchange ideas with wonderful colleagues!

Mayo Clinic embarks on a $5 billion project to revolutionize its flagship medical campus in #RochMN. Five new buildings will fuse traditional medical services with AI and digital tools, creating a 21st-century vision of clinical care. bit.ly/3uE2Wuk STAT

After a long wait, here we go: Pirtobrutinib for double exposed CLL. onclive.com/view/fda-appro…

Clinical characteristics and outcomes for the Lymphoma Epidemiology of Outcomes (LEO) cohort now available at the American Journal of Hematology. N=7735 patients with newly diagnosed #lymphoma enrolled from 2015-2020 and prospectively followed. onlinelibrary.wiley.com/doi/epdf/10.10…

6.5% of adults developed myeloid neoplasms (MN) post-CART therapy at a median interval of 10 months. Routine baseline data stratified low-, intermediate- & high-risk categories w/ cumulative incidence rate of MN of 0, 4, and 27 cases/100 patient-years. ja.ma/3USQFNx

What is the role of AI-ECG in #CardioOnc? Check out this Mayo Clinic #AF risk score study in CLL by Sameer Parikh Zachi Attia Wei Ding Saad kenderian Yucai Wang, MD, PhD Paul Hampel Amber Koehler, PA-C Prashant Kapoor Peter Noseworthy, MD Paul Friedman, MD Joerg Herrmann #JACCCardioOnc tinyurl.com/ekxw49ny

BREAKING: U.S. FDA Approves Liso-Cel for R/R Mantle Cell Lymphoma After 2 Lines of Therapy #lymsm #FDAApproved onclive.com/view/fda-appro…

Yucai Wang, MD, PhD, on Richter Transformation of CLL: Findings on Combination Therapy With an Immune Checkpoint Inhibitor ascopost.com/videos/2024-as… #leusm #leukemia #hematology #ASCO24 Yucai Wang, MD, PhD Mayo Clinic Mayo Clinic Comprehensive Cancer Center

❓ What is the benefit of #rituximab maintenance in patients With #MCL? Yucai Wang, MD, PhD, of Mayo Clinic, discusses his study on rituximab maintenance presented at #ASCO24! 📺 Watch the full interview here: buff.ly/4cksYDd

U.S. Food and Drug Administration Grants Second Approval for EPKINLY® (epcoritamab-bysp) to Treat Patients with Relapsed or Refractory Follicular Lymphoma prnewswire.com/news-releases/…

Bierman’s Brain Trivia - ERAS edition (Pineapple Cup Lymphoma Jeopardy) at #PPLC24.

September 15 is #WorldLymphomaAwarenessDay – a day to celebrate our community and to look ahead toward a future free from lymphoma. Join us today in raising your voice and spreading awareness: lymphoma.org/aboutus/bcam/ #BloodCancerAwarenessMonth